겸상 적혈구 빈혈 신속 POC 검사 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 기술별, 용도별, 기관 유형별, 최종 용도별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Rapid Point-of-Care Testing for Sickle Cell Anemia Market Growth & Trends:

The global rapid point-of-care testing for sickle cell anemia market size is expected to reach USD 522.83 million by 2030, registering a CAGR of 9.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Sickle Cell Disease (SCD) is a genetic blood disorder that results in the production of abnormally shaped red blood cells, leading to severe pain, anemia, and potential organ damage due to these sickle-shaped cells obstructing blood flow. India, according to the Journal of Hematology and Allied Science (JHAS), has one of the highest frequencies of the sickle B-globin allele. Early and accurate detection of SCD is critical for effective management and treatment. Traditional diagnostic methods often require specialized healthcare facilities and well-equipped laboratories, which may be inaccessible in resource-limited areas. This challenge has driven the growth of rapid point-of-care (POC) testing technologies, offering a more efficient and accessible alternative for diagnosing SCD.

POC testing offers several benefits, including fast results, ease of use, and suitability for decentralized healthcare settings. These features are particularly advantageous in regions with high SCD prevalence, where early diagnosis and intervention can substantially improve patient outcomes. By enabling timely detection, POC testing helps in better disease management, reducing the risk of severe complications and mortality associated with undiagnosed SCD. Furthermore, POC tests play a key role in newborn screening programs, helping to identify affected infants at birth and begin treatment immediately. Recent advancements in lateral flow immunoassays (LFIA) have significantly improved the diagnosis of SCD, particularly in low-resource settings. One innovative development is the multiplexed, allele-specific recombinase polymerase amplification (RPA) assay, which uses a lateral flow readout to detect multiple mutations in the B-globin gene, the primary cause of SCD, offering an efficient and accurate rapid diagnostic method. Additionally, integrating optical nanoparticles into LFIA platforms has enhanced the sensitivity and specificity of these tests, making them powerful diagnostic tools for SCD and other diseases.

Another notable innovation is the E-junction lateral flow immunoassay, designed for large-scale SCD screening in low- and middle-income countries (LMICs). This affordable, user-friendly POC device can diagnose healthy individuals, SCD patients, and carriers using just a single drop of whole blood. Its cost-effectiveness and reliability make it ideal for areas with limited access to traditional diagnostic methods, helping address the high mortality rates caused by delayed diagnoses. Similarly, the Sickle SCAN POC device demonstrates impressive sensitivity and specificity in detecting hemoglobin variants HbA, HbS, and HbC. It works effectively with both liquid blood and dried blood spots (DBS), even in samples containing high levels of fetal hemoglobin (HbF), making it an excellent choice for widespread screening in resource-constrained regions. The HemoTypeSC test, another promising tool for early SCD detection, is also highly sensitive and specific, particularly useful for large-scale screening programs. Mobile health units and community outreach programs, often led by NGOs, are also integral to providing rapid POC testing in resource-poor settings. These efforts not only enhance access to diagnostic services but also raise awareness about SCD and the importance of early intervention. Moreover, partnerships between NGOs and private companies have helped subsidize diagnostic tests, making them more affordable and scalable across various healthcare environments.

Targeted initiatives, such as the National Sickle Cell Anaemia Elimination Mission (NSCAEM), aim to eradicate sickle cell anemia as a public health issue by 2047 through universal screening, awareness campaigns, and improved disease management. The mission aims to screen about 70 million people aged 0-40, initially focusing on high-prevalence states like Gujarat and Maharashtra, while collaborating with the National Health Mission (NHM) for effective resource utilization.

Rapid Point-of-Care Testing for Sickle Cell Anemia Market Report Highlights:

• Based on type, the lateral flow immunoassay segment led the market in 2024 with a 51.66% share, due to its affordability, ease of use, and fast, accurate results. LFIA's ability to detect multiple hemoglobin variants and its suitability for low-resource settings contribute to its increasing adoption in global diagnostics.
• Based on technology, the hemoglobin electrophoresis segment led the market in 2024 with a 48.99% share, driven by its high accuracy in detecting hemoglobinopathies. As a reliable diagnostic method, it allows for precise identification of sickle cell disease and other hemoglobin variants, making it crucial for early intervention and disease management.
• Based on age group, the newborn screening (12 months and below) segment led the market in 2024 and is expected to witness the fastest CAGR during the forecast period, due to growing awareness and the importance of early diagnosis. Early detection through POC testing allows for prompt treatment, reducing complications and improving long-term outcomes for affected infants.
• The government laboratories sector type segment is experiencing significant growth, driven by national initiatives and technological advancements. The Indian Council of Medical Research (ICMR) has endorsed existing POC tests for sickle cell disease screening, encouraging states to implement one or two-level screening approaches.
• The hospitals & clinics end use segment is experiencing substantial growth, driven by the increasing prevalence of sickle cell disease and the demand for timely diagnostics.
• Based on distribution channel, the Business-to-Business (B2B) segment is experiencing significant growth, driven by increasing demand for accessible and efficient diagnostic solutions. Companies are forming strategic partnerships to expand their product offerings and reach broader markets.
• North America dominated the global Rapid point-of-care testing for sickle cell anemia industry with a revenue share of 43.97% in 2024, driven by increasing demand for accessible and efficient diagnostic solutions. This expansion is attributed to factors such as the rising prevalence of chronic diseases, advancements in diagnostic technologies, and increased funding from government and private institutions.
• Companies like BioMedomics and Silver Lake Research are leading the way with highly sensitive and specific tests, such as Sickle SCAN and HemoTypeSC, respectively, while others are leveraging global distribution networks to reach underserved populations. The market is poised for growth as these players work to enhance diagnostic capabilities, reduce turnaround times, and support early intervention efforts for sickle cell disease

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Technology
  • 1.2.3. Age group
  • 1.2.4. Sector Type
  • 1.2.5. End Use
  • 1.2.6. Distribution Channel
  • 1.2.7. Regional scope
  • 1.2.8. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type Outlook
  • 2.2.2. Technology Outlook
  • 2.2.3. Age Group Outlook
  • 2.2.4. Sector Type
  • 2.2.5. End Use Outlook
  • 2.2.6. Distribution Channel
  • 2.2.7. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Rapid Point-of-Care Testing for Sickle Cell Anemia Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising demand for personalized medicine and genomic research
    • 3.2.1.2. Growing prevalence of sickle cell disease (SCD)
    • 3.2.1.3. Advancements in diagnostic technology
    • 3.2.1.4. Government and NGO initiatives for early point-of-care (POC) screening
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Limited accessibility to advanced technologies
• 3.3. Rapid Point-of-Care Testing for Sickle Cell Anemia Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Lateral Flow Immunoassay
    • 4.4.1.1. Lateral Flow Immunoassay market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Paper-Based Rapid Diagnostics
    • 4.4.2.1. Paper-Based Rapid Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Others
    • 4.4.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Technology Estimates & Trend Analysis

• 5.1. Technology Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Technology Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Hemoglobin Electrophoresis
    • 5.4.1.1. Hemoglobin Electrophoresis market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Polymerase Chain Reaction (PCR)
    • 5.4.2.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Isothermal Amplification Assays
    • 5.4.3.1. Isothermal Amplification Assays market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Application Estimates & Trend Analysis

• 6.1. Application Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Application Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Newborn Screening (12 months and below)
    • 6.4.1.1. Newborn Screening (12 months and below) market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Adult Screening (25 to 60 years)
    • 6.4.2.1. Adult Screening (25 to 60 years) market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Other Age Groups (1 to 25 & Above 60 years)
    • 6.4.3.1. Other Age Groups (1 to 25 & Above 60 years) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Sector Type Estimates & Trend Analysis

• 7.1. Sector Type Market Share, 2024 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Sector Type Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Government Labs
    • 7.4.1.1. Government Labs market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Private Labs
    • 7.4.2.1. Private Labs market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Corporate Labs
    • 7.4.3.1. Corporate Labs market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. PPP (Public-Private-Partnerships)
    • 7.4.4.1. PPP (Public-Private-Partnerships) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: End Use Estimates & Trend Analysis

• 8.1. End Use Market Share, 2024 & 2030
• 8.2. Segment Dashboard
• 8.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by End Use Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.4.1. Research Institutions
    • 8.4.1.1. Research Institutions market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Hospitals & Clinics
    • 8.4.2.1. Hospitals & Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. Diagnostic Laboratories
    • 8.4.3.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Homecare Settings
    • 8.4.4.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Others
    • 8.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Distribution Channel Estimates & Trend Analysis

• 9.1. Distribution Channel Market Share, 2024 & 2030
• 9.2. Segment Dashboard
• 9.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Distribution Channel Outlook
• 9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 9.4.1. B2B (Business-to-Business)
    • 9.4.1.1. B2B (Business-to-Business) market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.2. B2C (Business-to-Consumer)
    • 9.4.2.1. B2C (Business-to-Consumer) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Regional Estimates & Trend Analysis

• 10.1. Regional Market Share Analysis, 2024 & 2030
• 10.2. Regional Market Dashboard
• 10.3. Global Regional Market Snapshot
• 10.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 10.5. North America
  • 10.5.1. North America: SWOT Analysis
  • 10.5.2. U.S.
    • 10.5.2.1. Key country dynamics
    • 10.5.2.2. Regulatory framework
    • 10.5.2.3. Competitive scenario
    • 10.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.5.3. Canada
    • 10.5.3.1. Key country dynamics
    • 10.5.3.2. Regulatory framework
    • 10.5.3.3. Competitive scenario
    • 10.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.5.4. Mexico
    • 10.5.4.1. Key country dynamics
    • 10.5.4.2. Regulatory framework
    • 10.5.4.3. Competitive scenario
    • 10.5.4.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 10.6. Europe
  • 10.6.1. Europe: SWOT Analysis
  • 10.6.2. UK
    • 10.6.2.1. Key country dynamics
    • 10.6.2.2. Regulatory framework
    • 10.6.2.3. Competitive scenario
    • 10.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6.3. Germany
    • 10.6.3.1. Key country dynamics
    • 10.6.3.2. Regulatory framework
    • 10.6.3.3. Competitive scenario
    • 10.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6.4. France
    • 10.6.4.1. Key country dynamics
    • 10.6.4.2. Regulatory framework
    • 10.6.4.3. Competitive scenario
    • 10.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6.5. Italy
    • 10.6.5.1. Key country dynamics
    • 10.6.5.2. Regulatory framework
    • 10.6.5.3. Competitive scenario
    • 10.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6.6. Spain
    • 10.6.6.1. Key country dynamics
    • 10.6.6.2. Regulatory framework
    • 10.6.6.3. Competitive scenario
    • 10.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6.7. Norway
    • 10.6.7.1. Key country dynamics
    • 10.6.7.2. Regulatory framework
    • 10.6.7.3. Competitive scenario
    • 10.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6.8. Sweden
    • 10.6.8.1. Key country dynamics
    • 10.6.8.2. Regulatory framework
    • 10.6.8.3. Competitive scenario
    • 10.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6.9. Denmark
    • 10.6.9.1. Key country dynamics
    • 10.6.9.2. Regulatory framework
    • 10.6.9.3. Competitive scenario
    • 10.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 10.7. Asia Pacific
  • 10.7.1. Asia Pacific: SWOT Analysis
  • 10.7.2. Japan
    • 10.7.2.1. Key country dynamics
    • 10.7.2.2. Regulatory framework
    • 10.7.2.3. Competitive scenario
    • 10.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7.3. China
    • 10.7.3.1. Key country dynamics
    • 10.7.3.2. Regulatory framework
    • 10.7.3.3. Competitive scenario
    • 10.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7.4. India
    • 10.7.4.1. Key country dynamics
    • 10.7.4.2. Regulatory framework
    • 10.7.4.3. Competitive scenario
    • 10.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7.5. Australia
    • 10.7.5.1. Key country dynamics
    • 10.7.5.2. Regulatory framework
    • 10.7.5.3. Competitive scenario
    • 10.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7.6. South Korea
    • 10.7.6.1. Key country dynamics
    • 10.7.6.2. Regulatory framework
    • 10.7.6.3. Competitive scenario
    • 10.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7.7. Thailand
    • 10.7.7.1. Key country dynamics
    • 10.7.7.2. Regulatory framework
    • 10.7.7.3. Competitive scenario
    • 10.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 10.8. Latin America
  • 10.8.1. Latin America: SWOT Analysis
  • 10.8.2. Brazil
    • 10.8.2.1. Key country dynamics
    • 10.8.2.2. Regulatory framework
    • 10.8.2.3. Competitive scenario
    • 10.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.8.3. Argentina
    • 10.8.3.1. Key country dynamics
    • 10.8.3.2. Regulatory framework
    • 10.8.3.3. Competitive scenario
    • 10.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 10.9. MEA
  • 10.9.1. MEA: SWOT Analysis
  • 10.9.2. South Africa
    • 10.9.2.1. Key country dynamics
    • 10.9.2.2. Regulatory framework
    • 10.9.2.3. Competitive scenario
    • 10.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.9.3. Saudi Arabia
    • 10.9.3.1. Key country dynamics
    • 10.9.3.2. Regulatory framework
    • 10.9.3.3. Competitive scenario
    • 10.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.9.4. UAE
    • 10.9.4.1. Key country dynamics
    • 10.9.4.2. Regulatory framework
    • 10.9.4.3. Competitive scenario
    • 10.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.9.5. Kuwait
    • 10.9.5.1. Key country dynamics
    • 10.9.5.2. Regulatory framework
    • 10.9.5.3. Competitive scenario
    • 10.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Recent Developments & Impact Analysis, By Key Market Participants
• 11.2. Company/Competition Categorization
• 11.3. Vendor Landscape
  • 11.3.1. List of key distributors and channel partners
  • 11.3.2. Key customers
  • 11.3.3. Key company market share analysis, 2024
  • 11.3.4. BIOMEDOMICS INC.
    • 11.3.4.1. Company overview
    • 11.3.4.2. Financial performance
    • 11.3.4.3. Services benchmarking
    • 11.3.4.4. Strategic initiatives
  • 11.3.5. Silver Lake Research Corporation
    • 11.3.5.1. Company overview
    • 11.3.5.2. Financial performance
    • 11.3.5.3. Services benchmarking
    • 11.3.5.4. Strategic initiatives
  • 11.3.6. Bio-Rad Laboratories, Inc.
    • 11.3.6.1. Company overview
    • 11.3.6.2. Financial performance
    • 11.3.6.3. Services benchmarking
    • 11.3.6.4. Strategic initiatives
  • 11.3.7. Trivitron Healthcare
    • 11.3.7.1. Company overview
    • 11.3.7.2. Financial performance
    • 11.3.7.3. Services benchmarking
    • 11.3.7.4. Strategic initiatives
  • 11.3.8. Hemex Health
    • 11.3.8.1. Company overview
    • 11.3.8.2. Financial performance
    • 11.3.8.3. Services benchmarking
    • 11.3.8.4. Strategic initiatives
  • 11.3.9. Sysmex Corporation
    • 11.3.9.1. Company overview
    • 11.3.9.2. Financial performance
    • 11.3.9.3. Services benchmarking
    • 11.3.9.4. Strategic initiatives
  • 11.3.10. EKF Diagnostics Holdings plc.
    • 11.3.10.1. Company overview
    • 11.3.10.2. Financial performance
    • 11.3.10.3. Services benchmarking
    • 11.3.10.4. Strategic initiatives
  • 11.3.11. HemoCue America (Danaher)
    • 11.3.11.1. Company overview
    • 11.3.11.2. Financial performance
    • 11.3.11.3. Services benchmarking
    • 11.3.11.4. Strategic initiatives
  • 11.3.12. Rapid Point-of-Care Testing for Sickle Cell Anemias Inc
    • 11.3.12.1. Company overview
    • 11.3.12.2. Financial performance
    • 11.3.12.3. Services benchmarking
    • 11.3.12.4. Strategic initiatives